Understanding the mechanism of action of the EP4 antagonist in cancer immunotherapy in combination with the C-IC concept would be a useful procedure when considering therapeutic strategy, drug regimen combination, or radiotherapy in the clinical environment. This evidence concerns the gene PTGER4 and cancer.